Kesmalea Therapeutics

London, United Kingdom · Founded 2020 · Privately Held (backing)

Developer of a pipeline of therapeutics designed to transform large protein degraders into small molecules for targeted protein degradation. Kesmalea Therapeutics is based in London, United Kingdom and was founded in 2020. Its last known valuation is $39 million. It has raised $37.8 million.

Last price · $/share
—
Implied valuation
$39.0M
Total raised
$37.8M
Last round
—

Who backs Kesmalea Therapeutics?

3 investors
InvestorType
Oxford Science EnterprisesVenture capital
BioInnovation InstituteOther
Syncona—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Kesmalea Therapeutics investors

3 investors are on record for Kesmalea Therapeutics, including Oxford Science Enterprises, BioInnovation Institute and Syncona.

Free account
More of Kesmalea Therapeutics with a free account
  • ·Watch Kesmalea Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 3 firms already write checks for companies like Kesmalea Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View